Recently in Australia and many countries worldwide, the accessibility of infliximab for indications within IBD has increased, alongside an increasing trend to use accelerated doses and shorter dose intervals to regain and/or achieve remission in certain disease subtypes[ 4 , 5 ].
← all excerpts
Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
1
—
—